Department of Hematology/Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, OH.
Associate Staff, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
Cleve Clin J Med. 2021 Dec 2;88(12):664-668. doi: 10.3949/ccjm.88a.20201.
The current American Society of Hematology (ASH) guidelines for the management of patients with immune thrombocytopenic purpura (ITP) are an update to the 2011 guidelines. The updates focus on treating patients with ITP without bleeding in both outpatient and inpatient settings, including those with newly diagnosed, persistent, and chronic ITP refractory to first-line therapy. Recommendations for therapy include corticosteroids, intravenous immunoglobulins, anti-D immunoglobulin, rituximab, splenectomy, and thrombopoietin-receptor agonists, as well as observation.
目前，美国血液学会（ASH）发布了新版《成人免疫性血小板减少症（ITP）管理指南》，取代了 2011 年版指南。新版指南重点在于更新了门诊和住院患者中无出血症状的 ITP 患者的治疗方案，包括新诊断、持续性和慢性 ITP 患者，以及一线治疗无效的患者。治疗推荐包括皮质激素、静脉注射免疫球蛋白、抗-D 免疫球蛋白、利妥昔单抗、脾切除术和血小板生成素受体激动剂，以及观察。
